News and Trends 22 Jul 2022Beyond Biotech podcast 6: Mogrify, +ND Capital, Poolbeg Pharma On this week’s podcast, our guests are Jeremy Skillington, CEO of Poolbeg Pharma; Dani Bach, and Eric Moessinger, both partners at +ND Capital; and Louise Modis, chief scientific officer at Mogrify. Poolbeg Pharma gets approval for severe influenza drug trial Poolbeg Pharma, a clinical stage infectious disease pharmaceutical company, has received ethics and competent authority […] July 22, 2022 Share WhatsApp Twitter Linkedin Email
News and Trends 18 Jul 2022 FORTY51 Ventures closes $43M biotech fund and announces first investment FORTY51 Ventures has announced the closing of FORTY51 Ventures I, raising $43 million in its first close. FORTY51’s core strategy focuses on company formation and early-stage investments in biotech with geographic emphasis on Switzerland, France and Germany. FORTY51 Ventures will lead or co-lead early rounds (seed and series A) of its growing portfolio, which will […] July 18, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 13 Jul 2022 The biggest European biotech investments in June 2022 Oncology and AI-guided drug discovery firms roped in the biggest biotech investments in Europe in June 2022. The leading private rounds went to companies including ImCheck Therapeutics, MiroBio and Charm Therapeutics. In June 2022, we saw bigger private biotech investments in Europe than in May. ImCheck Therapeutics took the top spot; the firm raised an […] July 13, 2022 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 4 Jul 2022 U.S. biotech financing drops 46% in Q1 compared to 2021 Venture financing deal value for U.S.-headquartered biotech companies dipped by 46% in Q1 2022 compared to Q1 2021, according to analysis from GlobalData. The data and analytics company said the decrease was due to venture capital firms becoming more selective in their investments due to the current economic and geopolitical uncertainties. Mariam Shwea, business fundamentals […] July 4, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 16 Jun 2022 Gimv creates new fund for life science companies European investment company Gimv has launched its fifth investment platform with a focus on venture capital investments in innovative life sciences companies. Gimv said after growth in its existing healthcare platform, a dedicated life sciences platform will strengthen its role in the international life science venture capital ecosystem. The company added its key investment focus […] June 16, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jun 2022 The top European biotech investments in May 2022 Biotech investments in Europe jumped in May 2022 with a large initial public offering from the US/UK firm PepGen. Meanwhile, oncology companies Tubulis, Domain Therapeutics, and EngImmune Therapeutics topped the private biotech investment rounds. Public stock markets remain in a volatile state for biotech companies, with a lot of uncertainty remaining over widespread inflation. Against […] June 8, 2022 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 17 May 2022 US Giant Apollo Bags Billion-Euro Partnership with Sofinnova As biotech investment slows following a record-breaking year, the Paris-based Sofinnova Partners has landed a €1B collaboration deal with the US investment heavyweight Apollo to nurture life sciences companies. Cementing the trend for transatlantic deals between biotech investors, the US asset manager Apollo has entered into a billion-Euro partnership with the European venture capitalist (VC) […] May 17, 2022 - 3 minutesmins - By Anita Chakraverty Share WhatsApp Twitter Linkedin Email
News and Trends 22 Apr 2022 European Biotech Investors Brace for Volatility in 2022 After gathering huge investment funds in 2021, European biotech investors took a breather in the first quarter of 2022, with the plan to steadily fund private biotechs amid a tumultuous public market. The last two years have seen a record-breaking amount of money flowing to biotech investors, with almost €10B reaching European life science funders […] April 22, 2022 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 17 Mar 2022 €80M Series B Establishes European Champion in Radiopharmaceuticals Big European venture capital firms Jeito, Forbion, and Inkef Capital have teamed up to propel the local radiopharmaceutical scene by investing €80M in the Belgian firm Precirix. Europe has a long history of expertise in the development of radiopharmaceutical drugs. One of the pioneers in the field was Advanced Accelerator Applications (AAA) in France. AAA […] March 17, 2022 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 15 Mar 2022 Biotech Stocks in “Total Eclipse” as Financial Pressures Mount More than a year after biotech stock indices peaked, the markets are worse than ever. Meanwhile, rumors of an impending wave of opportunistic biotech acquisitions are yet to materialize. In February of last year, biotech stocks across Europe and the US saw the end of a pandemic-fuelled growth spurt. Since then, the stock growth of […] March 15, 2022 - 6 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Opinion 14 Mar 2022 The Secrets to 50 Years of Success in Life Sciences Investment The European life sciences venture capital firm Sofinnova Partners is celebrating its 50th birthday this year. Sofinnova’s Chairman and Managing Partner, Antoine Papiernik, outlines key lessons the company has learned in its long history in the biotech industry. Meet a couple who have been married for 50 years and most of us, I imagine, would […] March 14, 2022 - 7 minutesmins - By Antoine Papiernik Share WhatsApp Twitter Linkedin Email
News and Trends 18 Feb 2022 Belgian VC Fund Leads Investment Wave in Japanese Biotech As US and European investor interest in Japanese biopharma startups spikes, the Belgian venture capital firm Newton Biocapital has launched a €150M fund to harness synergy between European and Japanese life sciences. Japan boasts a world-class technology industry in addition to a thriving life sciences scene. The nation hosts large companies including Takeda, Eisai, and […] February 18, 2022 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email